Mizuho maintains Axsome Therapeutics at Outperform, lowers price target to $272 from $284
Mizuho kept its Outperform rating on Axsome Therapeutics but reduced its price target to $272 from $284, a 4.2% decrease. The new target suggests a 94.8% upside from the Nov 3 close of $139.61. Recent analyst price targets for the company range from $220 to $273.
How this was made
The 30-second read
Why it matters
The downgrade reflects Mizuho's revised outlook, potentially prompting short‑term selling.
Market read
A modest analyst downgrade with limited immediate market impact.
What to watch
No new clinical data or earnings released; the change is purely analyst opinion.
Background
Axsome Therapeutics (AXSM) is a biotech company; analyst price‑target updates are routine.
Ticker impact
Mizuho lowered its price target for Axsome Therapeutics to $272 from $284, a new analyst action.
likely slight pressure as the market prices in the lower target.
Analyst price‑target cuts typically lead to short‑term bearish sentiment.
Market effects
Minimal impact on the broader biotech sector.
U.S. market only.
Low
Counterpoint
Investors may view the target cut as an overreaction and hold the stock.
Key entities
- AnalystMizuho
Equity research firm issuing the target cut.
